• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion.

作者信息

Boddy A V, Cole M, Pearson A D, Idle J R

机构信息

Cancer Research Unit, Medical School, University of Newcastle upon Tyne, UK.

出版信息

Cancer Chemother Pharmacol. 1995;36(1):53-60. doi: 10.1007/BF00685732.

DOI:10.1007/BF00685732
PMID:7720176
Abstract

It has often been reported that the oxazaphosphorines ifosfamide and cyclophosphamide induce their own metabolism. This phenomenon was studied in 21 paediatric patients over 35 courses of therapy. All patients received 9 gm-2 of ifosfamide as a continuous infusion over 72 h. Plasma concentrations of parent drug and of the major metabolite in plasma, 3-dechloroethylifosfamide (3DC) were determined, using a quantitative thin-layer chromatography (TLC) technique. A one-compartment model was fitted simultaneously to both ifosfamide and 3DC data. The model included a time-dependent clearance term, increasing asymptotically from an initial value to a final induced clearance and characterised by a first-order rate constant. A time lag, before induction of clearance began, was determined empirically. Metabolite kinetics were characterised by an elimination rate constant for the metabolite and a composite parameter comprising a formation clearance, proportional to the time-dependent clearance of parent drug, divided by the volume of distribution of the metabolite. Thus, the parameters to estimate were the volume of distribution of parent drug (V), initial clearance (Cli), final clearance (Cls), the rate constant for changing clearance (Kc), the elimination rate constant for the metabolite (Km) and Vm/fm, the metabolite volume of distribution divided by the fractional clearance to 3DC. The model of drug and metabolite kinetics produced a good fit to the data in 22 of 31 courses. In a further 4 courses an auto-inductive model for parent drug alone could be used. In the remaining courses, auto-induction could be demonstrated, but there were insufficient data to fit the model. For some patients this was due to a long time lag (up to 54 h) relative to the infusion time. The time lag varied from 6 to 54 (median, 12)h and values for the other parameters were Cli, 3.27 +/- 2.52 lh-1 m-2, Cls, 7.50 +/- 3.03 lh-1 m-2, V, 22.0 +/- 11.0 1 m-2, Kc, 0.086 +/- 0.074 h-1; Km, 0.159 +/- 0.077 h-1 and Vm/fm, 104 +/- 82 1m-2. The values of Kc correspond to a half-life of change in clearance ranging from 2 to 157 h, although for the majority of the patients the half-life was less than 7 h and a new steady-state level was achieved during the 72 h infusion period. This model provides insight into the time course of enzyme induction during ifosfamide administration, which may continue for up to 10 days in some protocols.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

相似文献

1
The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion.
Cancer Chemother Pharmacol. 1995;36(1):53-60. doi: 10.1007/BF00685732.
2
Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children.
Cancer Res. 1993 Aug 15;53(16):3758-64.
3
Pharmacokinetic modelling of ifosfamide administered by continuous infusion on 5 days at the dose of 6 g/m2.
Anticancer Res. 1999 Jan-Feb;19(1B):837-42.
4
Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach.异环磷酰胺及其脱氯乙基化和羟基化代谢产物在恶性疾病儿童中的群体药代动力学:一种稀疏采样方法。
Clin Pharmacokinet. 2001;40(8):615-25. doi: 10.2165/00003088-200140080-00005.
5
Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration.
Cancer Chemother Pharmacol. 1996;38(2):147-54. doi: 10.1007/s002800050463.
6
Comparison of continuous infusion and bolus administration of ifosfamide in children.
Eur J Cancer. 1995;31A(5):785-90. doi: 10.1016/0959-8049(95)00090-6.
7
Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma.
Eur J Clin Pharmacol. 2001 Sep;57(6-7):467-77. doi: 10.1007/s002280100322.
8
Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism.分次给予异环磷酰胺治疗会使异环磷酰胺代谢随时间增加。
Br J Clin Pharmacol. 1990 Nov;30(5):725-32. doi: 10.1111/j.1365-2125.1990.tb03842.x.
9
Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients.
Eur J Cancer. 1995;31A(1):69-76. doi: 10.1016/0959-8049(94)00300-t.
10
Metabolism and pharmacokinetics of oxazaphosphorines.恶唑磷类化合物的代谢与药代动力学
Clin Pharmacokinet. 2000 Apr;38(4):291-304. doi: 10.2165/00003088-200038040-00001.

引用本文的文献

1
A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TAS-114.纳入自动诱导的半机械论群体药代动力学和药效学模型用于 TAS-114 的剂量合理性论证。
CPT Pharmacometrics Syst Pharmacol. 2022 May;11(5):604-615. doi: 10.1002/psp4.12747. Epub 2021 Dec 23.
2
Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria.人群药代动力学研究显示,青蒿琥酯、双氢青蒿素和咯萘啶在治疗无并发症恶性疟原虫感染的卢旺达人孕妇中的应用。
Antimicrob Agents Chemother. 2018 Sep 24;62(10). doi: 10.1128/AAC.00518-18. Print 2018 Oct.
3

本文引用的文献

1
Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard.环磷酰胺通过丙烯醛和磷酰胺氮芥的联合作用调节大鼠肝脏细胞色素P450 2C11和类固醇5α-还原酶活性及信使核糖核酸水平。
Cancer Res. 1993 Jun 1;53(11):2490-7.
2
Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions.
Biochem Pharmacol. 1993 Feb 24;45(4):853-61. doi: 10.1016/0006-2952(93)90169-w.
3
Ifosfamide, mesna, and nephrotoxicity in children.异环磷酰胺、美司钠与儿童肾毒性
Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study.
帕唑帕尼的暴露量因异环磷酰胺依赖性药物相互作用而降低:一项 I 期研究的结果。
Br J Cancer. 2014 Feb 18;110(4):888-93. doi: 10.1038/bjc.2013.798. Epub 2013 Dec 24.
4
Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients.异基因造血干细胞移植受者中脂质体两性霉素 B 和卡泊芬净的群体药代动力学。
Antimicrob Agents Chemother. 2012 Jan;56(1):536-43. doi: 10.1128/AAC.00265-11. Epub 2011 Nov 14.
5
Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics.基于 UPLC-ESI-QTOFMS 的代谢组学研究在小鼠体内环磷酰胺和异环磷酰胺的比较代谢。
Biochem Pharmacol. 2010 Oct 1;80(7):1063-74. doi: 10.1016/j.bcp.2010.06.002. Epub 2010 Jun 10.
6
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.由于同时给予异环磷酰胺导致舒尼替尼暴露量减少:舒尼替尼联合异环磷酰胺治疗晚期实体瘤患者的 I 期和药代动力学研究结果。
Br J Cancer. 2010 Jun 8;102(12):1699-706. doi: 10.1038/sj.bjc.6605696. Epub 2010 May 18.
7
A mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects.一种基于机制的群体药代动力学模型,用于表征米哚妥林及其代谢物在人体中的时间依赖性药代动力学。
Clin Pharmacokinet. 2008;47(12):807-16. doi: 10.2165/0003088-200847120-00005.
8
A mechanism-based integrated pharmacokinetic enzyme model describing the time course and magnitude of phenobarbital-mediated enzyme induction in the rat.一种基于机制的综合药代动力学酶模型,用于描述大鼠体内苯巴比妥介导的酶诱导的时间进程和程度。
Pharm Res. 2006 Mar;23(3):521-32. doi: 10.1007/s11095-005-9571-z. Epub 2006 Mar 15.
9
Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity.发育中肾脏中的细胞色素P450 3A和2B6:对异环磷酰胺肾毒性的影响
Pediatr Nephrol. 2005 Jul;20(7):872-85. doi: 10.1007/s00467-004-1807-3. Epub 2005 May 4.
10
Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer.异环磷酰胺的药代动力学和代谢与通过彗星试验评估的癌症患儿DNA损伤的关系。
Br J Cancer. 2005 May 9;92(9):1626-35. doi: 10.1038/sj.bjc.6602554.
J Clin Oncol. 1993 Jan;11(1):173-90. doi: 10.1200/JCO.1993.11.1.173.
4
Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein.
Cancer Res. 1993 Feb 1;53(3):472-6.
5
Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children.
Cancer Res. 1993 Aug 15;53(16):3758-64.
6
Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy.分次静脉注射异环磷酰胺治疗患者中异环磷酰胺、4-羟基异环磷酰胺、氯乙醛以及2-和3-去氯乙基异环磷酰胺的比较药代动力学
Cancer Chemother Pharmacol. 1993;33(1):36-42. doi: 10.1007/BF00686020.
7
Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes.细胞色素P-450 2B和3A在人肝微粒体中对环磷酰胺和异环磷酰胺的差异激活作用。
Cancer Res. 1993 Dec 1;53(23):5629-37.
8
Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide.参与异环磷酰胺活化和N-去氯乙基化的主要人肝细胞色素P450的鉴定。
Biochem Pharmacol. 1994 Mar 29;47(7):1157-63. doi: 10.1016/0006-2952(94)90387-5.
9
Drug metabolite kinetics.药物代谢动力学。
Pharmacol Ther. 1981;15(3):521-52. doi: 10.1016/0163-7258(81)90056-5.
10
Decreased plasma half-life of cyclophosphamide during repeated high-dose administration.
Cancer Chemother Pharmacol. 1983;10(3):192-3. doi: 10.1007/BF00255760.